# A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

Source: https://onco.cc/trials/nct07543055/  
OnCo record `nct07543055` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of BPX-601 run by Regeneron Pharmaceuticals, now recruiting.

## Summary

A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread is a phase 1 interventional study registered as NCT07543055 by Regeneron Pharmaceuticals, with 36 participants planned, started 2026-09-08. Conditions recorded: Prostate Cancer. Interventions recorded: BPX-601.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07543055
- Phase: 1
- Setting: A Phase 1, Open-Label, Dose-Escalation Study of BPX-601, an Anti-PSCA CAR T Cell Drug Product, in Relapsed/Refractory Metastatic Castration-Resistant Prostate Cancer
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT07543055: https://clinicaltrials.gov/study/NCT07543055

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [BPX-601](https://onco.cc/drugs/bpx-601/)
- companies: [Bellicum Pharmaceuticals](https://onco.cc/companies/bellicum/), [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct07543055.json